The UK has been accused of acting in bad faith after backing away from an international agreement aimed at reducing the cost of drugs worldwide.
In the run-up to this month’s World Health Assembly – the decision-making body of the World Health Organization – member states spent three weeks negotiating the agreement aimed at increasing transparency over drug pricing, with the UK, United States, Germany, Japan and Switzerland demanding changes to the text.
However, when the final agreement was signed on Monday the UK, Germany and Hungary formally dissociated themselves from it.
The resolution urges member states to share information on the price they pay for medicines and devices in a bid to lower drug costs as well as ensure that all clinical trial results are published.
The resolution also requests that the WHO monitors the impact of transparency on affordability and availability of health products.